Recently, some VRK1 specific inhibitors, based on an aminopyridine scaffold, are functional at pharmacological concentrations that inhibit tumor cell growth [165] and effect similar to VRK1 depletion [159], however, still need testing to determine their therapeutic potential. The gene discussed is VRK1; the disease is neoplasm.